Talphera Inc. (TLPH) - Total Liabilities
Based on the latest financial reports, Talphera Inc. (TLPH) has total liabilities worth $11.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Talphera Inc. (TLPH) cash flow conversion to assess how effectively this company generates cash.
Talphera Inc. - Total Liabilities Trend (2008–2024)
This chart illustrates how Talphera Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check TLPH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Talphera Inc. Competitors by Total Liabilities
The table below lists competitors of Talphera Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GFG Resources Inc
V:GFG
|
Canada | CA$2.27 Million |
|
Nusa Konstruksi Enjiniring Tbk
JK:DGIK
|
Indonesia | Rp712.04 Billion |
|
Mondi PLC
LSE:MNDI
|
UK | GBX4.84 Billion |
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
India | Rs5.77 Billion |
|
Lider Faktoring AS
IS:LIDFA
|
Turkey | TL7.88 Billion |
|
Doctor Care Anywhere Group Plc
AU:DOC
|
Australia | AU$15.11 Million |
|
Canlan Ice Sports Corp.
TO:ICE
|
Canada | CA$80.61 Million |
|
Panorama Sentrawisata Tbk
JK:PANR
|
Indonesia | Rp724.87 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Talphera Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Talphera Inc. (TLPH) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Talphera Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Talphera Inc. (2008–2024)
The table below shows the annual total liabilities of Talphera Inc. from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $10.24 Million | +62.72% |
| 2023-12-31 | $6.29 Million | -75.50% |
| 2022-12-31 | $25.67 Million | -77.44% |
| 2021-12-31 | $113.79 Million | -6.77% |
| 2020-12-31 | $122.05 Million | -8.08% |
| 2019-12-31 | $132.77 Million | +14.18% |
| 2018-12-31 | $116.28 Million | +3.76% |
| 2017-12-31 | $112.06 Million | +6.39% |
| 2016-12-31 | $105.33 Million | +11.26% |
| 2015-12-31 | $94.67 Million | +138.11% |
| 2014-12-31 | $39.76 Million | +7.83% |
| 2013-12-31 | $36.87 Million | +20.21% |
| 2012-12-31 | $30.67 Million | +31.27% |
| 2011-12-31 | $23.37 Million | -67.87% |
| 2010-12-31 | $72.72 Million | +7.76% |
| 2009-12-31 | $67.48 Million | +20.48% |
| 2008-12-31 | $56.01 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more